Company makes bolt-on acquisition to enhance position in gout marketplace.
Takeda Pharmaceutical has agreed to acquire URL Pharma for an upfront payment of $800 million and future performance-based, contingent, earn-out payments. The company announced the deal last week.
URL Pharma’s lead product is Colcrys (colchicine), a drug used to treat and prevent gout flares. Net sales for Colcrys in calendar year 2011 were more than $430 million, accounting for a major portion of URL’s 2011 revenues of $600 million. The drug complements Takeda’s position in the gout marketplace with Uloric (febuxostat), which is used to lower blood uric acid levels in adults with gout.
URL is headquartered in Philadelphia and has approximately 500 employees. In addition, URL Pharma has a contracted sales force consisting of approximately 350 individuals. The deal is expected to close in 60 days.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.